

Resource Summary Report

Generated by [RRID](#) on Jul 30, 2026

Ms CD38 BUV563 90/CD38 50ug

RRID:AB_2870812

Type: Antibody

Proper Citation

BD Biosciences Cat# 741271, RRID:AB_2870812

Antibody Information

URL: http://antibodyregistry.org/AB_2870812

Proper Citation: BD Biosciences Cat# 741271, RRID:AB_2870812

Target Antigen: CD38

Host Organism: rat

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: Ms CD38 BUV563 90/CD38 50ug

Description: This monoclonal targets CD38

Target Organism: mouse

Clone ID: 90/CD38 (aka Ab90)

Antibody ID: AB_2870812

Vendor: BD Biosciences

Catalog Number: 741271

Record Creation Time: 20250819T204833+0000

Record Last Update: 20250819T205340+0000

Ratings and Alerts

No rating or validation information has been found for Ms CD38 BUV563 90/CD38 50ug.

No alerts have been found for Ms CD38 BUV563 90/CD38 50ug.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Isshiki Y, et al. (2025) EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function. *Cancer cell*, 43(1), 49.

Barisic D, et al. (2024) ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis. *Cancer cell*.

Venturutti L, et al. (2023) An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas. *Cancer discovery*, 13(1), 216.

Li J, et al. (2023) Cooperative super-enhancer inactivation caused by heterozygous loss of CREBBP and KMT2D skews B cell fate decisions and yields T cell-depleted lymphomas. *bioRxiv* : the preprint server for biology.